RESUMEN

In this work, Ru-promoted cobalt oxide catalysts with a nanotube morphology were prepared by a synthesis route based on the Kirkendall effect followed by an acid treatment and subsequent optimized Ru impregnation. The resulting samples were thoroughly characterized by means of N2 physisorption, X-ray energy-dispersive spectroscopy, X-ray diffraction, scanning electron microscopy techniques, X-ray photoelectron spectroscopy, and temperature-programmed techniques (O2-temperature-programmed desorption, H2-temperature-programmed reduction, and temperature-programmed oxidation) and evaluated in the gas-phase oxidation of 1,2-dichloroethane. It has been demonstrated that Ru addition improves the oxygen mobility as well as the amount of Co2+ and Oads species at the surface by the formation of the Ru-O-Co bond, which in turn governs the performance of the catalysts in the oxidation reaction. Moreover, the acid-etching favors the dispersion of the Ru species on the surface of the catalysts and strengthens the interaction among the noble metal and the cobalt oxide, thereby improving the thermal stability of the Ru-promoted oxides. Thus, the resulting catalysts are not only active, as the chlorinated pollutant is efficiently converted into deep oxidation products at relatively low temperatures, but also quite stable when operating for 120 h.

RESUMEN

Six ceria supports synthesized by various synthesis methodologies were used to deposit cobalt oxide. The catalysts were thoroughly characterized, and their catalytic activity for complete methane oxidation was studied. The supports synthesized by direct calcination and precipitation with ammonia exhibited the best textural and structural properties as well as the highest degree of oxidation. The remaining supports presented poorer textural properties to be employed as catalytic supports. The cobalt deposited over the first two supports presented a good dispersion at the external surface, which induced a significant redox effect that increased the number of Co3+ ions on their surface. Consequently, the presence of highly active lattice oxygen species on the surface of these catalysts was favored. Additionally, the optimal active catalyst (Co-DC) revealed a significant resistance to water vapor inhibition, owing to the high hydrophobicity of the ceria support.

RESUMEN

This non-interventional, prospective phase IV trial evaluated trabectedin in patients with soft tissue sarcoma (STS) in real-life clinical practice across Germany. The primary endpoints were progression-free survival (PFS) rates at 3 and 6 months, as defined by investigators. Overall, 128 patients from 19 German sites were evaluated for efficacy and 130 for safety. Median age was 58.5 years (range: 23-84) and leiomyosarcoma was the most frequent histotype (n = 45; 35.2%). Trabectedin was mostly used as second/third-line treatment (n = 91; 71.1%). Median PFS was 5.2 months (95% CI: 3.3-6.7), with 60.7% and 44.5% of patients free from progression at 3 and 6 months, respectively. Median overall survival was 15.2 months (95% CI: 9.6-21.4). One patient achieved a complete and 14 patients a partial response, conferring an objective response rate of 11.7%. Decreases in white blood cells (27.0% of patients), platelets (16.2%) and neutrophils (13.1%) and increased alanine aminotransferase (10.8%) were the most common trabectedin-related grade 3/4 adverse drug reactions. Two deaths due to pneumonia and sepsis were considered trabectedin-related. Trabectedin confers clinically meaningful activity in patients with multiple STS histotypes, comparable to that previously observed in clinical trials and other non-interventional studies, and with a manageable safety profile.

RESUMEN

Plitidepsin, a marine-derived cyclic-peptide, inhibits SARS-CoV-2 replication at nanomolar concentrations by targeting the host protein eukaryotic translation elongation factor 1A. Here, we show that plitidepsin distributes preferentially to lung over plasma, with similar potency against across several SARS-CoV-2 variants in preclinical studies. Simultaneously, in this randomized, parallel, open-label, proof-of-concept study (NCT04382066) conducted in 10 Spanish hospitals between May and November 2020, 46 adult hospitalized patients with confirmed SARS-CoV-2 infection received either 1.5 mg (n = 15), 2.0 mg (n = 16), or 2.5 mg (n = 15) plitidepsin once daily for 3 d. The primary objective was safety; viral load kinetics, mortality, need for increased respiratory support, and dose selection were secondary end points. One patient withdrew consent before starting procedures; 45 initiated treatment; one withdrew because of hypersensitivity. Two Grade 3 treatment-related adverse events were observed (hypersensitivity and diarrhea). Treatment-related adverse events affecting more than 5% of patients were nausea (42.2%), vomiting (15.6%), and diarrhea (6.7%). Mean viral load reductions from baseline were 1.35, 2.35, 3.25, and 3.85 log10 at days 4, 7, 15, and 31. Nonmechanical invasive ventilation was required in 8 of 44 evaluable patients (16.0%); six patients required intensive care support (13.6%), and three patients (6.7%) died (COVID-19-related). Plitidepsin has a favorable safety profile in patients with COVID-19.

Asunto(s)

RESUMEN

The combustion of lean methane was studied over palladium, rhodium, platinum, and ruthenium catalysts supported on hydroxyapatite (HAP). The samples were prepared by wetness impregnation and thoroughly characterized by BET, XRD, UV-Vis-NIR spectroscopy, H2-TPR, OSC, CO chemisorption, and TEM techniques. It was found that the Pd/HAP and Rh/HAP catalysts exhibited a higher activity compared with Pt/HAP and Ru/HAP samples. Thus, the degree of oxidation of the supported metal under the reaction mixture notably influenced its catalytic performance. Although Pd and Rh catalysts could be easily re-oxidized, the re-oxidation of Pt and Ru samples appeared to be a slow process, resulting in small amounts of metal oxide active sites. Feeding water and CO2 was found to have a negative effect, which was more pronounced in the presence of water, on the activity of Pd and Rh catalysts. However, the inhibiting effect of CO2 and H2O decreased by increasing the reaction temperature.

RESUMEN

Plitidepsin is a marine-derived cyclic-peptide that inhibits SARS-CoV-2 replication at low nanomolar concentrations by the targeting of host protein eEF1A (eukaryotic translation-elongation-factor-1A). We evaluated a model of intervention with plitidepsin in hospitalized COVID-19 adult patients where three doses were assessed (1.5, 2 and 2.5 mg/day for 3 days, as a 90-minute intravenous infusion) in 45 patients (15 per dose-cohort). Treatment was well tolerated, with only two Grade 3 treatment-related adverse events observed (hypersensitivity and diarrhea). The discharge rates by Days 8 and 15 were 56.8% and 81.8%, respectively, with data sustaining dose-effect. A mean 4.2 log10 viral load reduction was attained by Day 15. Improvement in inflammation markers was also noted in a seemingly dose-dependent manner. These results suggest that plitidepsin impacts the outcome of patients with COVID-19. ONE-SENTENCE SUMMARY: Plitidepsin, an inhibitor of SARS-Cov-2 in vitro , is safe and positively influences the outcome of patients hospitalized with COVID-19.

RESUMEN

PURPOSE: The noninterventional, prospective NIMES-ROC phase IV study (NCT02825420) evaluated trabectedin plus pegylated liposomal doxorubicin (PLD) in real-life clinical practice. PATIENTS AND METHODS: Eligible participants included adults with platinum-sensitive recurrent ovarian cancer (PS-ROC) who had received one or more cycles of trabectedin/PLD before inclusion according to the marketing authorization. The primary endpoint was progression-free survival (PFS) according to investigator criteria. RESULTS: Two hundred eighteen patients from five European countries were evaluated, 72.5% of whom were pretreated with at least two prior chemotherapy lines and received a median of six cycles of trabectedin/PLD (range: 1-24). Median PFS was 9.46 months (95% confidence interval [CI], 7.9-10.9), and median overall survival (OS) was 23.56 months (95% CI, 18.1-34.1). Patients not pretreated with an antiangiogenic drug obtained larger median PFS (p < .007) and OS (p < .048), largely owning to differences between the two populations. Twenty-four patients (11.0%) had a complete response, and 57 patients (26.1%) achieved a partial response for an objective response rate (ORR) of 37.2%. Fifty-nine patients (27.1%) had disease stabilization for a disease control rate of 64.2%. No statistically significant difference in PFS, OS, or ORR was observed by BRCA1/2 status and platinum sensitivity. Most common grade 3/4 adverse events (AEs) were neutropenia (30.3%), anemia (6.4%), thrombocytopenia (5.5%), and asthenia (5.0%). No deaths attributed to treatment-related AEs or unexpected AEs occurred. CONCLUSION: The combination of trabectedin/PLD represents a clinically meaningful and safe option for patients with PS-ROC regardless of prior treatment with an antiangiogenic drug, being comparable with previously observed outcomes in selected and less pretreated patients from clinical trials. IMPLICATIONS FOR PRACTICE: This noninterventional, prospective study, conducted in 57 reference sites across Europe, consistently confirmed that trabectedin plus pegylated liposomal doxorubicin (PLD) in routine clinical practice represents a clinically meaningful and safe option for women with platinum-sensitive recurrent ovarian cancer. Although the study population represented a heterogeneous, older, and more pretreated population than those in prospective clinical trials, the combination of trabectedin plus PLD induced comparable clinical benefits, with a similar and manageable safety profile. Overall, these findings show that trabectedin in combination with PLD maintains antitumor activity when administered to heavily pretreated patients in real-life clinical practice.

Asunto(s)

RESUMEN

Antecedentes: El Glioblastoma (GB) o astrocitoma grado IV, es un tumor agresivo que se origina de células gliales, con alto grado de malignidad, prevalencia menor al 1% en fosa posterior e incidencia menor al 0.5% de todos los GB. Actualmente se describen alrededor de 75 casos a nivel mundial. Descripción del caso clínico: Femenina, 24 años, referida a emergencia de Neurocirugía del Hospital Escuela Universitario, presentó cefalea holocraneana intensa, vómitos, náuseas, visión borrosa, vértigo y anorexia. Al examen neurológico mostró discreta adiadococinesia derecha y signos de papiledema. La tomografía axial computarizada cerebral evidenció lesión heterogénea en vermis extendido a hemisferio cerebeloso derecho, por lo que se realizó craniectomía suboccipital, abordaje transcerebelar, con citorreducción tumoral, encontrando masa vascularizada con componente quístico. Estudio anatomopatológico evidenció glioblastoma multiforme variante de células gigantes, confirmado con tinción de inmunohistoquímica (PFGA, CD34+ y vimentina). Paciente con buena evolución clínica postquirúrgica, egresada sin déficit neurológico. 16 meses después, presentó síndrome de recidiva tumoral y complicaciones, por lo que se reintervino en 4 ocasiones, posterior a recibir 30 dosis de radioterapia y 12 ciclos de quimioterapia, se reingresó con deterioro neurológico progresivo, signos meníngeos y síndrome de Parinaud, escala de Karnofsky (30 puntos), realizándose derivación ventrículo-peritoneal por compresión del IV ventrículo e hidrocefalia obstructiva secundaria, luego desarrolló neumonía intrahospitalaria, falleciendo a las dos semanas. Conclusiones: Es importante identificar la variante biológica del glioblastoma de forma temprana, para determinar pronóstico y acciones terapéuticas que influirán en la calidad de vida, así como la supervivencia...(AU)

Asunto(s)

RESUMEN

The present work addresses the influence of the support on the catalytic behavior of Co3O4-based catalysts in the combustion of lean methane present in the exhaust gases from natural gas vehicular engines. Three different supports were selected, namely γ-alumina, magnesia and ceria and the corresponding catalysts were loaded with a nominal cobalt content of 30 wt. %. The samples were characterized by N2 physisorption, wavelength dispersive X-ray fluorescence (WDXRF), X-ray diffraction (XRD), Raman spectroscopy, X-ray photoelectron spectroscopy (XPS) and temperature-programmed reduction with hydrogen and methane. The performance was negatively influenced by a strong cobalt-support interaction, which in turn reduced the amount of active cobalt species as Co3O4. Hence, when alumina or magnesia supports were employed, the formation of CoAl2O4 or Co-Mg mixed oxides, respectively, with a low reducibility was evident, while ceria showed a lower affinity for deposited cobalt and this remained essentially as Co3O4. Furthermore, the observed partial insertion of Ce into the Co3O4 lattice played a beneficial role in promoting the oxygen mobility at low temperatures and consequently the catalytic activity. This catalyst also exhibited a good thermal stability while the presence of water vapor in the feedstream induced a partial inhibition, which was found to be completely reversible.

RESUMEN

OBJETIVO: Evaluar el grado en que los sucesos adversos (SA) ligados a la asistencia sanitaria alcanzan al paciente y su severidad. Analizar los factores contribuyentes a la aparición de SA, la relación con el daño provocado y el grado de evitabilidad. DISEÑO: Estudio descriptivo retrospectivo. Emplazamiento: Servicio de Atención Primaria de Porriño desde enero de 2014 a abril de 2016. Participantes y/o contexto: Se incluyeron notificaciones de SA en el Sistema de Notificación y Aprendizaje para Seguridad del Paciente (SiNASP). MÉTODO: Variables de medida: incidente adverso (IA) si no alcanzó al paciente o no produjo daño, evento adverso (EA) si llegó al paciente con daño. Grado de daño clasificado como mínimo, menor, moderado, crítico y catastrófico. Evitabilidad registrada como escasa evidencia de ser evitable, 50% evitable y sólida evidencia de ser evitable. nálisis de datos: porcentajes y test de chi-cuadrado para variables cualitativas; p < 0,05 con SPSS.15 Fuente de datos: SiNASP. Consideraciones éticas: autorizado por el Comité de Ética de Investigación (2016/344). RESULTADOS: Se registraron 166 SA (50,0% hombres, 46,4% mujeres; edad media: 60,80 años). El 62,7% alcanzaron al paciente. EA: 45,8% produjeron daño mínimo y 2,4%, daño crítico. Los profesionales fueron factor contribuyente en el 71,7% de los EA, encontrándose tendencia a la asociación entre deficiente comunicación y ausencia de protocolos con el daño producido. Grado de evitabilidad: 96,4%. CONCLUSIONES: La mayoría de los SA alcanzaron al paciente, estando relacionados con la medicación, pruebas diagnósticas y errores de laboratorio. El grado de daño se asoció con problemas de comunicación, ausencia o deficiencia de protocolos y escasa cultura en seguridad

OBJECTIVE: To assess the extent of healthcare related adverse events (AEs), their effect on patients, and their seriousness. To analyse the factors leading to the development of AEs, their relationship with the damage caused, and their degree of preventability. DESIGN: Retrospective descriptive study. LOCATION: Porriño, Pontevedra, Spain, Primary Care Service, from January-2014 to April-2016. Participants and/or context: Reported AEs were entered into the Patient Safety Reporting and Learning System (SiNASP). METHOD: The variables measured were: Near Incident (NI) an occurrence with no effect or harm on the patient; Adverse Event (AE) an occurrence that affects or harms a patient. The level of harm is classified as minimal, minor, moderate, critical, and catastrophic. Preventability was classified as little evidence of being preventable, 50% preventable, and sound evidence of being preventable. Data analysis: percentages and Chi-squared test for qualitative variables; P < .05 with SPSS.15. Data source: SiNASP. Ethical considerations: approved by the Research Ethics Committee (2016/344). RESULTS: There were 166 recorded AEs (50.6% in males, and 46.4% in women. The mean age was 60.80 years). Almost two-thirds 62.7% of AEs affected the patient, with 45.8% causing minimal damage, while 2.4% caused critical damages. Healthcare professionals were a contributing factor in 71.7% of the AEs, with the trend showing that poor communication and lack of protocols were related to the damage caused. Degree of preventability: 96.4%. CONCLUSIONS: Most AEs affected the patient, and were related to medication, diagnostic tests, and laboratory errors. The level of harm was related to communication problems, lack of, or deficient, protocols and a poor safety culture

Asunto(s)

RESUMEN

Antecedentes: La microlitiasis es una afección pulmonar poco frecuente, caracterizada por acumulo de fosfatos de calcio en el interior de los alveolos pulmonares, originando cuerpos nodulares conocidos como microlitos, siendo esta su principal caracterís-tica. Destacando la poca relación Clínico Radiológica, dada su escasa documentación y relativamente poco estudio, es difícil su diag-nóstico y frecuentemente es confundida con otras entidades patológicas. Caso Clínico: Femenina de 38 años, hipertensa controlada con atenolol 100 mg vía oral día, exposición al humo de leña, con 6 meses de tos intermitente, seca, disnea y sibilancias nocturnas, se le practicó una tomografía que en la ventana mediastial se aprecia corazón de tamaño normal con algunas adenomegalias de pocos milímetros para órticos y peri traqueales no sospechosos y en la ventana pulmonar hay llenado alveolar homogéneo difuso bilateral, con engrosamiento nodular centro lobular y septal con calciicaciones inas de la pleura. La biopsia trasbronquial reporta espacios al-veolares con presencia de concentraciones laminares en piel de cebolla basóilos intra alveolares compatible con microlitiasis alveolar. Discusión: Identiicar estas particularidades nos permitiría realizar un abordaje temprano para evitar complicaciones iniciales de esta enfermedad, aunque no se conoce un tratamiento curativo...(AU)

Asunto(s)

RESUMEN

The active combustion catalyst that is based on 30 wt % cobalt oxide on mesoporous SBA-15 has been tested in 1,2-dichloropropane oxidation and is characterized by means of FT-IR (Fourier transform infrared spectroscopy) and ammonia-TPD (temperature-programmed desorption). In this work, we report the spectroscopic evidence for the role of surface acidity in chloroalkane conversion. Both Lewis acidity and weakly acidic silanol groups from SBA support are involved in the adsorption and initial conversion steps. Moreover, total oxidation reaction results in the formation of new Bronsted acidic sites, which are likely associated with the generation of HCl at high temperature and its adsorption at the catalyst surface. Highly dispersed Co oxide on the mesoporous support and Co-chloride or oxychloride particles, together with the presence of several families of acidic sites originated from the conditioning effect of reaction products may explain the good activity of this catalyst in the oxidation of Chlorinated Volatile Organic Compounds.

RESUMEN

Background and objectives: The main objective of this study was to assess the percentage of co-morbid nephropathy in type 2 diabetes patients using the CKD-EPI equation and to compare the clinical characteristics and treatments of patients with type 2 diabetes with nephropathy with those of patients without nephropathy Patients and methods: This was a cross-sectional analysis of the demographic and clinical data registered in the IDIBAPS Biobank database. Patients were considered to have nephropathy if the diagnosis was reported in their clinical history, albuminuria (>30 mg/g) was indicated as present in the last urine test available, or an estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73 m2 was calculated using the CKD-EPI equation. Results: Clinical data were obtained from 1,397 patients with a diagnosis of type 2 diabetes. The percentage of patients with nephropathy was 29.3% (N= 369) (95% confidence interval, 26.8% to 31.9%); however, only 109 (7.8%) patients had a nephropathy diagnosis reported in their clinical history. Compared with patients without nephropathy, patients with nephropathy have a higher mean age, higher frequency of diabetes complications and received insulin more frequently. Conclusion: Our results show that the percentage of type 2 diabetes patients with nephropathy was high and that this comorbidity was associated with a significantly higher frequency of diabetes macro- and microvascular complications (compared to diabetes patients without DKD) (AU)

Antecedentes y objetivo: El objetivo principal de este estudio fue evaluar el porcentaje de nefropatía en pacientes con diabetes tipo 2 utilizando la ecuación CKD-EPI y comparar las características clínicas y tratamientos de pacientes con diabetes tipo 2 con nefropatía con los de pacientes sin nefropatía. Pacientes y método: Se trata de un análisis transversal de los datos demográficos y clínicos registrados en la base de datos IDIBAPS Biobank. Se consideró que los pacientes tenían nefropatía diabética si el diagnóstico figuraba en su historia clínica, presentaban albuminuria (>30mg/g) en la última analítica de orina disponible o tenían un filtrado glomerular estimado (FGe) inferior a 60ml/min/1,73 m2 calculado usando la ecuación CKD-EPI. Resultados: Se obtuvieron datos clínicos de 1.397 pacientes con diagnóstico de diabetes tipo 2. El porcentaje de pacientes con nefropatía fue de 29,3% (N=369) (intervalo de confianza del 95%, 26,8% a 31,9%); sin embargo, sólo en 109 (7,8%) figuraba el diagnóstico de nefropatía en su historia clínica. En comparación con los pacientes sin nefropatía, los pacientes con nefropatía tienen una edad media más alta, mayor frecuencia de complicaciones relacionadas con la diabetes y recibieron insulina con mayor frecuencia. Conclusiones: Nuestros resultados muestran que el porcentaje de pacientes diabéticos de tipo 2 con nefropatía fue alto y que esta comorbilidad se asoció con una frecuencia significativamente mayor de complicaciones macro y microvasculares relacionadas con la diabetes (en comparación con pacientes diabéticos sin nefropatía) (AU)

Asunto(s)

RESUMEN

OBJECTIVE: To assess the extent of healthcare related adverse events (AEs), their effect on patients, and their seriousness. To analyse the factors leading to the development of AEs, their relationship with the damage caused, and their degree of preventability. DESIGN: Retrospective descriptive study. LOCATION: Porriño, Pontevedra, Spain, Primary Care Service, from January-2014 to April-2016. PARTICIPANTS AND/OR CONTEXT: Reported AEs were entered into the Patient Safety Reporting and Learning System (SiNASP). METHOD: The variables measured were: Near Incident (NI) an occurrence with no effect or harm on the patient; Adverse Event (AE) an occurrence that affects or harms a patient. The level of harm is classified as minimal, minor, moderate, critical, and catastrophic. Preventability was classified as little evidence of being preventable, 50% preventable, and sound evidence of being preventable. DATA ANALYSIS: percentages and Chi-squared test for qualitative variables; P<.05 with SPSS.15. DATA SOURCE: SiNASP. Ethical considerations: approved by the Research Ethics Committee (2016/344). RESULTS: There were 166 recorded AEs (50.6% in males, and 46.4% in women. The mean age was 60.80years). Almost two-thirds 62.7% of AEs affected the patient, with 45.8% causing minimal damage, while 2.4% caused critical damages. Healthcare professionals were a contributing factor in 71.7% of the AEs, with the trend showing that poor communication and lack of protocols were related to the damage caused. Degree of preventability: 96.4%. CONCLUSIONS: Most AEs affected the patient, and were related to medication, diagnostic tests, and laboratory errors. The level of harm was related to communication problems, lack of, or deficient, protocols and a poor safety culture.

Asunto(s)

RESUMEN

BACKGROUND AND OBJECTIVES: The main objective of this study was to assess the percentage of co-morbid nephropathy in type 2 diabetes patients using the CKD-EPI equation and to compare the clinical characteristics and treatments of patients with type 2 diabetes with nephropathy with those of patients without nephropathy PATIENTS AND METHODS: This was a cross-sectional analysis of the demographic and clinical data registered in the IDIBAPS Biobank database. Patients were considered to have nephropathy if the diagnosis was reported in their clinical history, albuminuria (>30 mg/g) was indicated as present in the last urine test available, or an estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73 m2 was calculated using the CKD-EPI equation. RESULTS: Clinical data were obtained from 1,397 patients with a diagnosis of type 2 diabetes. The percentage of patients with nephropathy was 29.3% (N= 369) (95% confidence interval, 26.8% to 31.9%); however, only 109 (7.8%) patients had a nephropathy diagnosis reported in their clinical history. Compared with patients without nephropathy, patients with nephropathy have a higher mean age, higher frequency of diabetes complications and received insulin more frequently. CONCLUSION: Our results show that the percentage of type 2 diabetes patients with nephropathy was high and that this comorbidity was associated with a significantly higher frequency of diabetes macro- and microvascular complications (compared to diabetes patients without DKD).

Asunto(s)

RESUMEN

La colitis seudomembranosa es una severa y a veces mortal afección que puede ocurrir tras la administración de antibióticos y supresión de la flora intestinal normal, seguida de colonización por Clostridium difficile; se caracteriza por la inflamación aguda y presencia de seudomembranas necróticas en la mucosa colónica. Se presenta el caso de un paciente varón de nueve años de edad, proveniente de una zona rural de Honduras, con antecedente de fiebre intermitente de cuatro semanas de evolución, escalofríos, mialgias, náuseas e ictericia de una semana de evolución. Atendido previamente en Centro de Atención Primaria, fue tratado con antipiréticos, sin mejoría. Al examen físico el paciente estaba lúcido, se halló hipotensión, taquicardia, y fiebre; dolor abdominal epigastrio y ambos hipocondrios a la palpación superficial y profunda, hepatomegalia, ictericia, petequias. En los exámenes de laboratorio se encontraron pancitopenia severa, falla renal aguda, trastornos hidroelectrolíticos e hipoalbuminemia. Fue ingresado al servicio de urgencias pediátricas. Luego de una mala evolución clínica, falleció diecinueve después del ingreso. La autopsia reveló seudomembranas necróticas colónicas e imagen histológica de tipo volcán compatibles con colitis seudomembranosa.

Pseudomembranous colitis is a severe and often fatal condition that may occur after the administration of some antimicrobial agents. There is suppression of the normal intestinal flora, followed by colonization by Clostridium difficile; and this condition is characterized by acute inflammation and presence of necrotic tissue pseudomembranes in the colon mucosa. We present the case of a nine-year-old boy from a rural area in Honduras, with a history of intermittent fever lasting four weeks, accompanied by chills, myalgia, nausea, and jaundice in the last week. He was previously seen in a primary care center with antipyretics, without improvement. The physical examination showed a lucid patient with hypotension, tachycardia, and fever; epigastric and bilateral hypochondrial abdominal pain on superficial and deep palpation was evidenced. Hepatomegaly, jaundice, and petechiae were also found. Laboratory tests showed severe pancytopenia, acute renal failure, hydroelectrolytic disturbances, and hypoalbuminemia. The patient was admitted to the Pediatric Urgency service. After a poor progression, he passed away nineteen days after admission. The necropsy showed necrotic pseudomembranes in the colon and a histological image resembling the shape of a volcano, compatible with pseudomembranous colitis.

Asunto(s)

RESUMEN

No disponible

Asunto(s)

RESUMEN

No disponible

Asunto(s)